Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia.

Damien G, Hélène H, Jean-Michel D, Céline B, Carlos G, Fabienne G, Anne S, Christian C, Bernard C, François M.

J Thromb Thrombolysis. 2017 Jan 10. doi: 10.1007/s11239-016-1471-z. [Epub ahead of print]

PMID:
28074413
2.

Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.

Chou S, Hwang SJ, Carlos G, Wakade D, Fernandez-Penas P.

Am J Dermatopathol. 2017 Jan;39(1):23-27. doi: 10.1097/DAD.0000000000000587.

PMID:
28045749
3.

Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.

Hwang SJ, Anforth R, Carlos G, Fernandez-Peñas P.

Actas Dermosifiliogr. 2017 Jan - Feb;108(1):6-16. doi: 10.1016/j.ad.2016.05.019. English, Spanish.

PMID:
27642030
4.

Method validation and determination of lisdexamfetamine and amphetamine in oral fluid, plasma and urine by LC-MS/MS.

Comiran E, Barreto F, Meneghini LZ, Carlos G, Fröehlich PE, Limberger RP.

Biomed Chromatogr. 2016 Aug 12. doi: 10.1002/bmc.3812. [Epub ahead of print]

PMID:
27518755
5.

Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma: a prospective, consecutive, cohort study of 168 cases.

Cheng HM, Lo S, Scolyer R, Meekings A, Carlos G, Guitera P.

Br J Dermatol. 2016 Dec;175(6):1290-1300. doi: 10.1111/bjd.14714.

PMID:
27146027
6.

PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases.

Wakade DV, Carlos G, Hwang SJ, Chou S, Hui R, Fernandez-Peñas P.

Melanoma Res. 2016 Aug;26(4):421-4. doi: 10.1097/CMR.0000000000000263.

PMID:
27135655
7.

Pharmacokinetics study of mazindol in plasma, oral fluid, and urine of volunteers.

de Oliveira MH, Ferreira PC, Carlos G, Salazar FR, Bergold AM, Pechansky F, Limberger RP, Fröehlich PE.

Eur J Clin Pharmacol. 2016 Aug;72(8):945-51. doi: 10.1007/s00228-016-2055-8.

PMID:
27066959
8.

Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.

Hwang SJ, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P.

Melanoma Res. 2016 Aug;26(4):413-6. doi: 10.1097/CMR.0000000000000260.

PMID:
27031539
9.

Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.

Hwang SJ, Carlos G, Wakade D, Sharma R, Fernandez-Penas P.

Melanoma Res. 2016 Aug;26(4):417-20. doi: 10.1097/CMR.0000000000000261.

PMID:
27031538
10.

Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions.

Ali M, Anforth R, Senetiner F, Carlos G, Fernandez-Penas P.

Exp Dermatol. 2016 May;25(5):394-5. doi: 10.1111/exd.12975. No abstract available.

PMID:
26896751
11.

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.

Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, Carlino MS, Kefford R, Fernandez-Penas P.

J Am Acad Dermatol. 2016 Mar;74(3):455-61.e1. doi: 10.1016/j.jaad.2015.10.029.

PMID:
26793994
12.

Validation and application of a liquid chromatography-electrospray ionization mass spectrometric method for determination of mazindol in human plasma and urine.

de Oliveira MH, Ferreira PC, Carlos G, Salazar FR, Bergold AM, Pechansky F, Limberger RP, Fröehlich PE.

J Pharmacol Toxicol Methods. 2016 May-Jun;79:1-6. doi: 10.1016/j.vascn.2015.12.003.

PMID:
26718151
13.

Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.

Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, Fernandez-Peñas P.

JAMA Dermatol. 2015 Oct;151(10):1103-9. doi: 10.1001/jamadermatol.2015.1745.

PMID:
26200476
14.

Tinea hidden by a vemurafenib-induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone.

Anforth R, Carlos G, Eiris N, Clements A, Fernandez-Peñas P.

Med J Aust. 2015 Jul 6;203(1):41-2. No abstract available.

PMID:
26126567
15.

A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.

Carlos G, Anforth R, Chou S, Clements A, Fernandez-Peñas P.

Melanoma Res. 2015 Jun;25(3):265-8. doi: 10.1097/CMR.0000000000000155.

PMID:
25831416
16.

Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.

Anforth R, Menzies A, Byth K, Carlos G, Chou S, Sharma R, Scolyer RA, Kefford R, Long GV, Fernandez-Peñas P.

J Am Acad Dermatol. 2015 May;72(5):809-15.e1. doi: 10.1016/j.jaad.2015.01.018.

PMID:
25748298
17.

Dabrafenib-associated necrobiotic granulomatous reaction.

Carlos G, Anforth R, Chou S, Fernandez-Peñas P.

Australas J Dermatol. 2014 Nov;55(4):306-8. doi: 10.1111/ajd.12226. No abstract available.

PMID:
25399793
18.

Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.

Anforth RM, Carlos GR, Scolyer RA, Chou S, Fernandez-Peñas P.

Melanoma Res. 2015 Feb;25(1):91-4. doi: 10.1097/CMR.0000000000000127.

PMID:
25380183
19.

Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.

Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Peñas P.

Br J Dermatol. 2015 Jan;172(1):239-43. doi: 10.1111/bjd.13200.

PMID:
25040674
20.

Determination of mazindol in human oral fluid by high performance liquid chromatography-electrospray ionization mass spectrometry.

de Oliveira MH, Carlos G, Bergold AM, Pechansky F, Limberger RP, Fröehlich PE.

Biomed Chromatogr. 2014 Aug;28(8):1064-9. doi: 10.1002/bmc.3120.

PMID:
24458547
Items per page

Supplemental Content

Loading ...
Support Center